June 26, 2018 09:45 AM EDT

Roche's Sophie Kornowski joins Chris Viehbacher at Gurnet Point; FDA will give Roche's groundbreaking flu drug speedy review

John Carroll

Editor & Founder

→ We now know where Sophie Kornowski is headed. The top dealmaking exec at Roche left recently, leaving James Sabry with a chance to move …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche's Sophie Kornowski joins Chris Viehbacher at Gurnet Point; FDA will give Roche's groundbreaking flu drug speedy review

John Carroll

Editor & Founder

Sign up to read this article for free.

AbbVie declares third Phase 3 Parkinson’s win from Cerevel takeover

ADC scientist who paved the way for Daiichi’s Enhertu dies

AstraZeneca reveals first clinical data for bispecific T cell engager from TeneoTwo buyout

Biosecure bill is left out of end-of-year defense package, dealing blow to chances

Beam shares results from seven patients who received gene-edited sickle cell therapy

The key to faster, more impactful research? Put patients in the driver’s seat

Roche's So­phie Ko­rnows­ki joins Chris Viehbach­er at Gur­net Point; FDA will give Roche's ground­break­ing flu drug speedy re­view

John Carroll

Editor & Founder

Sign up to read this article for free.

Ab­b­Vie de­clares third Phase 3 Parkin­son’s win from Cerev­el takeover

ADC sci­en­tist who paved the way for Dai­ichi’s En­her­tu dies

As­traZeneca re­veals first clin­i­cal da­ta for bis­pe­cif­ic T cell en­gager from TeneoT­wo buy­out

Biose­cure bill is left out of end-of-year de­fense pack­age, deal­ing blow to chances

Beam shares re­sults from sev­en pa­tients who re­ceived gene-edit­ed sick­le cell ther­a­py

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

Roche's Sophie Kornowski joins Chris Viehbacher at Gurnet Point; FDA will give Roche's groundbreaking flu drug speedy review

AbbVie declares third Phase 3 Parkinson’s win from Cerevel takeover

ADC scientist who paved the way for Daiichi’s Enhertu dies

AstraZeneca reveals first clinical data for bispecific T cell engager from TeneoTwo buyout

Biosecure bill is left out of end-of-year defense package, dealing blow to chances

Beam shares results from seven patients who received gene-edited sickle cell therapy

The key to faster, more impactful research? Put patients in the driver’s seat